Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.37 |
| ▸ | HTR3B | O95264 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.37 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.37 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1067715 | 0.79 | CYP3A4 (0.48) | CYP1A2LMNAPMP22KMT2AHDAC6 | |
| SCHEMBL836969 | 0.78 | HTR3E (0.62) | IDO1SMN1; SMN2HTR3EHTR3BHTR3A | |
| SCHEMBL1580473 | 0.78 | TAAR1 (0.49) | IDO1MAPK8HDAC8HDAC6 | |
| SCHEMBL838275 | 0.78 | TAAR1 (0.44) | RAB9AIDO1MAPK8MEN1KMT2A | |
| SCHEMBL480288 | 0.76 | CYP3A4 (0.35) | CYP1A2CYP2D6IDO1SIGMAR1PMP22 | |
| SCHEMBL434982 | 0.76 | HDAC8 (0.56) | IDO1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL10396581 | 0.74 | MEN1 (0.52) | IDO1SIGMAR1LMNAMEN1KMT2A | |
| SCHEMBL28503212 | 0.74 | MEP1B (0.55) | — | |
| SCHEMBL4685156 | 0.73 | CYP1A2 (0.46) | CYP1A2CYP2D6CYP2C19THPORAB9A | |
| SCHEMBL23588035 | 0.73 | XIAP (0.45) | CYP1A2CYP2D6CYP2C19RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101955470-B | Potentiators of glutamate receptors | LILLY CO ELI | 2012-06-13 | — | — | CN | disclosed |
| EP-2441762-A1 | Potentiators of Glutamate Receptors | Eli Lilly and Company (US) | 2012-04-18 | — | — | EP | disclosed |
| EP-1817301-B1 | POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2012-02-01 | — | — | EP | disclosed |
| CN-101955470-A | Glutamate receptor potentiators | LILLY CO ELI | 2011-01-26 | — | — | CN | disclosed |
| US-7816523-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-10-19 | — | — | US | disclosed |
| CN-101061106-B | Glutamate receptor potentiators | LILLY CO ELI | 2010-09-29 | — | — | CN | disclosed |
| US-7803938-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2010-09-28 | — | — | US | disclosed |
| US-20090318481-A1 | Potentiators Of Glutamate Receptors | AICHER THOMAS DANIEL | 2009-12-24 | — | — | US | disclosed |
| US-20090318483-A1 | Potentiators Of Glutamate Receptors | AICHER THOMAS DANIEL | 2009-12-24 | — | — | US | disclosed |
| US-7598423-B2 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | ARRAY BIOPHARMA, INC. | 2008-06-12 | — | — | US | disclosed |
| CN-101061106-A | Glutamate receptor potentiators | LILLY CO ELI (US) | 2007-10-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | GRM1, GRIN1, GRM2 | CYP1A2 1022/4885CYP2D6 810/4885CYP2C19 693/4885 |
| US-20090318481-A1 | Potentiators Of Glutamate Receptors | GRIK1, GRIK2, GRIK4 | CYP1A2 1836/4885CYP2D6 1973/4885CYP2C19 1042/4885 |
| US-20090318483-A1 | Potentiators Of Glutamate Receptors | GRIK1, GRIK2, GRIK4 | CYP1A2 1836/4885CYP2D6 1973/4885CYP2C19 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.